Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 18

1451P - Neoadjuvant and adjuvant pembrolizumab (pembro) + chemotherapy (chemo) for locally advanced gastric or gastroesophageal junction (G/GEJ) cancer: Patient-reported outcomes (PROs) from the phase III KEYNOTE-585 study

Date

14 Sep 2024

Session

Poster session 18

Topics

Clinical Research;  Immunotherapy

Tumour Site

Gastric Cancer;  Gastro-Oesophageal Junction Cancer

Presenters

Kohei Shitara

Citation

Annals of Oncology (2024) 35 (suppl_2): S878-S912. 10.1016/annonc/annonc1603

Authors

K. Shitara1, S.Y. Rha2, L.S. Wyrwicz3, T. Oshima4, N. Karaseva5, M. Osipov6, H. Yasui7, H. Yabusaki8, S. Afanasyev9, Y. Park10, S. Al-Batran11, T. Yoshikawa12, P.E. Yanez Weber13, M. Di Bartolomeo14, S. Lonardi15, Y. Guan16, A. Valderrama17, C. Shih18, X. Fang19, Y. Bang20

Author affiliations

  • 1 Department Of Gastrointestinal Oncology, National Cancer Center Hospital East, 277-8577 - Kashiwa/JP
  • 2 Medical Oncology Department, Yonsei Cancer Center, Yonsei University College of Medicine, Yonsei University Health System, 03722 - Seoul/KR
  • 3 Dept Of Oncology And Radiotherapy, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 - Warsaw/PL
  • 4 Department Of Gastrointestinal Surgery, Kanagawa Cancer Center, 2410815 - Yokohama/JP
  • 5 Chemotherapy, St Petersburg State Budgetary Institution of Healthcare Clinical Oncology Dispensary, 198255 - Saint-Petersburg/RU
  • 6 Outpatient Chemotherapy Department, Leningrad Regional Clinical Hospital, 194291 - Saint-Petersburg/RU
  • 7 Medical Oncology Department, Kobe City Medical Center General Hospital, 650-0047 - Kobe/JP
  • 8 Gastroenterological Surgery, Niigata Cancer Center Hospital, 951-8566 - Niigata/JP
  • 9 Abdominal Oncology, Tomsk National Research Medical Center of the Russian Academy of Sciences, 634009 - Tomsk/RU
  • 10 Surgery, Chonnam National University College of Medicine, 58128 - Jeonam/KR
  • 11 Institute Of Clinical Cancer Research, Krankenhaus Nordwest UCT-University Cancer Center, 60488 - Frankfurt/DE
  • 12 Gastric Surgery, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 13 Departamento De Oncologia, Centro Integrado de Pesquisa em Oncologia, Universidad de La Frontera, James Lind Cancer Research Center, 4810297 - Temuco/CL
  • 14 Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 - Milan/IT
  • 15 Oncology Department, Veneto Institute of Oncology IOV-IRCCS, 35128 - Padova/IT
  • 16 Epidemiology, Merck & Co., Inc. - Rahway, 07065 - Rahway/US
  • 17 Core, Merck, 07065 - Rahway/US
  • 18 Oncology, Merck & Co., Inc. - Upper Gwynedd Site, 07065 - Rahway/US
  • 19 Bards, Merck & Co., Inc. - Corporate Headquarters, 07065 - Rahway/US
  • 20 Internal Medicine, Seoul National University College of Medicine, 03080 - Seoul/KR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1451P

Background

In the randomized, phase 3 KEYNOTE-585 study (NCT03221426), perioperative pembro + chemo vs placebo (pbo) + chemo significantly improved pCR (diff, 10.9%; 95% CI, 7.5-14.8; P<0.00001), with no new safety signals in patients (pts) with locally advanced G/GEJ cancer. Prespecified exploratory PROs are reported.

Methods

Eligible adults had untreated locally advanced resectable G/GEJ adenocarcinoma and ECOG PS of 0 or 1. Pts were randomly assigned 1:1 to receive neoadjuvant 200 mg pembro IV + chemo or pbo + chemo Q3W for 3 cycles, then surgery, adjuvant pembro + chemo or pbo + chemo Q3W for 3 cycles, then adjuvant pembro or pbo alone Q3W for 11 cycles. The main cohort had pembro or pbo + cisplatin-based doublet chemo; the safety cohort had pembro or pbo + FLOT. Health-related quality of life (HRQoL) was evaluated in pts who had ≥1 dose of treatment and ≥1 PRO assessment. PRO end points were least squares mean (LSM) change from baseline to week 6 (neoadjuvant) or week 39 (adjuvant) in subscales of EORTC QLQ-C30, EORTC QLQ-STO22, and EQ-5D-5L VAS. Week 6 was the only analysis time in the neoadjuvant phase; week 39 was the latest time in the adjuvant phase when completion was ≥60% and compliance was ≥80%. Improvement was a positive (EORTC QLQ-C30, EQ-5D-5L VAS) or negative (EORTC QLQ-STO22) LSM change. Database cutoff was Feb 16, 2024.

Results

The PRO analysis comprised 980 pts (pembro + chemo, n=490; pbo + chemo, n=490). Median follow-up was 58.6 months (range, 36.7-75.8) for pembro + chemo and 58.5 (36.7-75.8) for pbo + chemo. LSM changes from baseline in the combined cohorts are in the table. Table: 1451P

Change from baselinea in LSM (95% CI) to week 6 (neoadjuvant) or 39 (adjuvant)

Neoadjuvant pembro + chemo Neoadjuvant pbo + chemo Adjuvant pembro + chemo Adjuvant pbo + chemo
QLQ-C30 GHS/QoL n=489 n=488 n=374 n=371
–1.68 (–3.73 to 0.36) –4.73 (–6.79 to –2.68) 4.23 (1.99-6.47) 4.12 (1.94-6.31)
QLQ-STO22 pain scale n=487 n=486 n=374 n=371
–3.14 (–4.95 to –1.34) –1.35 (–3.16 to 0.46) –5.30 (–7.45 to –3.15) –3.03 (–5.13 to –0.93)
EQ-5D-5L VAS n=489 n=490 n=373 n = 371
–2.28 (–3.86 to –0.70) –3.08 (–4.67 to –1.49) 3.52 (1.86-5.18) 3.37 (1.75-5.00)

aInitiation of therapy (neoadjuvant) or surgery (adjuvant).

Conclusions

Pembro + chemo did not worsen HRQoL vs pbo + chemo for pts with untreated locally advanced resectable G/GEJ cancer enrolled in KEYNOTE-585. Combined with the safety and efficacy results from KEYNOTE-585, HRQoL data support continued exploration of perioperative pembro combinations in these pts.

Clinical trial identification

NCT03221426.

Editorial acknowledgement

Medical writing assistance was provided by Shane Walton, PhD, CMPP, and Holly C. Cappelli, PhD, CMPP, of ApotheCom (Yardley, PA, USA).

Legal entity responsible for the study

Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Funding

Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Disclosure

K. Shitara: Financial Interests, Personal, Advisory Board: Bristol Myers Squibb, Takeda, Ono Pharmaceutical, MSD, Novartis, Daiichi Sankyo, Amgen, Guardant Health Japan Corp, Astellas Pharma Inc., Astellas, Bayer, AstraZeneca, Zymeworks Biopharmaceuticals Inc., ALX Oncology Inc.; Financial Interests, Personal, Invited Speaker: Bristol Myers Squibb, Janssen, AstraZeneca, Eli Lilly, Astellas, Ono Pharmaceutical; Financial Interests, Institutional, Research Grant: Astellas, Ono Pharmaceutical, Daiichi Sankyo, Taiho Pharmaceutical, Chugai Pharmaceutical, MSD, Eisai, Amgen, PRA Health Sciences. S.Y. Rha: Financial Interests, Personal, Advisory Board: Indivumed, Amgen, LG biochemical, Astellas, beringer Ingelheim; Financial Interests, Personal, Invited Speaker: MSD, Daiichi Sankyo; Financial Interests, Personal, Steering Committee Member: Amgen; Financial Interests, Institutional, Funding: MSD, Lilly; Financial Interests, Institutional, Research Grant: BMS, Daiichi Sankyo; Financial Interests, Institutional, Local PI: Indivumed, AstraZeneca; Financial Interests, Other, Drug supply for clinical trial: Merck; Financial Interests, Institutional, Coordinating PI, Drug supply for clincal trial: MSD; Financial Interests, Institutional, Local PI, drug supply for clinical trial: Zymeworks; Financial Interests, Institutional, Local PI, drug supply for clincial trial: BeiGene; Financial Interests, Local PI: Roche. L.S. Wyrwicz: Financial Interests, Personal, Advisory Role: GSK, Servier; Financial Interests, Personal, Speaker’s Bureau: Bristol Myers Squibb; Financial Interests, Personal, Other, Travel: Servier; Financial Interests, Personal, Other, Honoraria: BeiGene, Bristol Myers Squibb, MSD. T. Oshima: Financial Interests, Personal, Invited Speaker: Taiho, Astellas; Financial Interests, Personal, Writing Engagement: Astellas; Financial Interests, Personal, Other, research grant: Taiho, Kyowa Kirin, Chugai, Nihon Kayaku. M. Osipov: Non-Financial Interests, Personal, Principal Investigator: Leningrad Regional Clinical Hospital. H. Yasui: Financial Interests, Personal, Invited Speaker: Taiho Pharmaceutical, Chugai Pharma, Bristol Myers Squibb, Daiichi Sankyo, Terumo, Eli Lilly Japan, Merck Biopharma, Yakult Honsha, Bayer Yakuhin, Takeda Pharmaceutical; Financial Interests, Personal, Advisory Board: Ono Pharmaceutical; Financial Interests, Institutional, Local PI: MSD, Daiichi Sankyo, Ono Pharmaceutical, Astellas Pharma, Amgen, AstraZeneca. S. Al-Batran: Financial Interests, Personal, Advisory Board: Lilly, Bristol Myers Squibb, MSD Sharp & Dohme; Financial Interests, Personal, Invited Speaker: MCI Deutschland GmbH; Financial Interests, Personal, Ownership Interest, CEO: Institut für Klinische Krebsforschung IKF GmbH; Financial Interests, Institutional, Research Grant: Sanofi, Roche, Celgene, Lilly, Eurozyto, Immutep, Ipsen, Bristol Myers Squibb, MSD Sharp & Dohme, AstraZeneca, German Cancer Aid (Krebshilfe), German Research Foundation, Federal Ministry of Education and Research. M. Di Bartolomeo: Financial Interests, Institutional, Advisory Board: MSD, Lilly Spa, BMS; Financial Interests, Institutional, Principal Investigator: MSD; Financial Interests, Institutional, Research Grant: Lilly Spa. S. Lonardi: Financial Interests, Personal, Advisory Board: Amgen, Merck Serono, Lilly, Servier, AstraZeneca, MSD, Incyte, Daiichi Sankyo, Bristol Myers Squibb, Astellas, GSK, Takeda, Bayer, Rottapharm; Financial Interests, Personal, Invited Speaker: Pierre Fabre, GSK, Roche, Servier, Amgen, Bristol Myers Squibb, Incyte, Lilly, Merck Serono, MSD, AstraZeneca; Financial Interests, Institutional, Coordinating PI: Amgen, Merck Serono, Bayer, Roche, Lilly, AstraZeneca, Bristol Myers Squibb; Non-Financial Interests, Member of Board of Directors, Italian No-Profit Oncology Research Foundation supporting academic Clinical trials: GONO Foundation. Y. Guan: Financial Interests, Personal, Full or part-time Employment: Merck & Co., Inc.; Financial Interests, Personal, Stocks/Shares: Merck & Co., Inc. A. Valderrama: Financial Interests, Personal, Full or part-time Employment: Merck & Co., Inc. C. Shih: Financial Interests, Personal, Full or part-time Employment: Merck & Co., Inc.; Financial Interests, Personal, Stocks/Shares: Merck & Co., Inc.; Financial Interests, Personal, Proprietary Information: Merck & Co., Inc. X. Fang: Financial Interests, Personal, Full or part-time Employment: Merck & Co., Inc. Y. Bang: Financial Interests, Personal, Advisory Role: Astellas, Amgen, Hanmi, Daewong, SK Biopharm. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.